Authors : Hanaa Khalil Sacheat; A A Esaa; Sana B. Mohammed

Volume/Issue : Volume 9 - 2024, Issue 11 - November

Google Scholar : https://tinyurl.com/ymskvfbe

Scribd : https://tinyurl.com/mtk2r7ss

DOI : https://doi.org/10.5281/zenodo.14408360

Abstract : Calprotectin makes approximately 60% of the cytosolic protein in neutrophils, which are found throughout the human body, and to a smaller extent in monocytes and macrophages. The primary fluids that contain these cells include plasma, urine, feces, saliva, and cerebrospinal fluid. Calcprotectin affects a wide range of physiological processes, such as inflammation, apoptosis, cancer, immunological regulation, and cell differentiation. Calprotectin is regarded as a positive acute phase protein and is involved in inflammation.When distinguishing between organic and functional causes of gastrointestinal illness through symptoms or clinical examination is challenging, faecal calprotectin can be helpful. In clinical practice, it is employed to distinguish between irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), as the latter has a distinct pathophysiology despite sharing many of the same signs and symptoms. IBD is classified as an organic disease because it affects the intestinal wall, while IBS is classified as a functional condition because it affects gut motility. Faecal calprotectin also has the useful property of being a good marker of mucosal healing or inflammatory recurrence when its levels vary.Faecal calprotectin can therefore be used to monitor IBD patients and identify those who are at risk of relapsing. Fecal calprotectin is strongly associated with ulcerative colitis but weakly with Crohn's disease, where the difference was diagnosed in terms of laboratory parameters and symptoms. Both diseases are considered among the most current health problems for children and adolescents, as they are found in larger numbers among these ages than among adults.

Keywords : Inflammatory Bowel Disease − Crohn’s Disease - Fecal Calprotectin.

References :

1. Ludvigsson, J.F., et al., Swedish inflammatory bowel disease register (SWIBREG)–a nationwide quality register. Scandinavian journal of gastroenterology, 2019. 54(9): p. 1089-1101.
2. Sipponen, T., et al., Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. Scandinavian journal of gastroenterology, 2010. 45(3): p. 325-331.
3. D’Incà, R., et al., Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. International journal of colorectal disease, 2007. 22: p. 429-437.
4. Lin, J.-F., et al., Meta-analysis: fecal calprotectin for assessment of inflammatory bowel disease activity. Inflammatory bowel diseases, 2014. 20(8): p. 1407-1415.
5. Mosli, M.H., et al., C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis. Official journal of the American College of Gastroenterology| ACG, 2015. 110(6): p. 802-819.
6. Fagerhol, M.K., I. Dale, and T. Anderson, Release and quantitation of a leucocyte derived protein (L1). Scandinavian Journal of Haematology, 1980. 24(5): p. 393-398.
7. Dale, I., M.K. Fagerhol, and I. Naesgaard, Purification and partial characterization of a highly immunogenic human leukocyte protein, the L1 antigen. European Journal of Biochemistry, 1983. 134(1): p. 1-6.
8. Schäfer, B.W. and C.W. Heizmann, The S100 family of EF-hand calcium-binding proteins: functions and pathology. Trends in biochemical sciences, 1996. 21(4): p. 134-140.
9. Dhas, D.B.B., B.V. Bhat, and D.B. Gane, Role of calprotectin in infection and inflammation. Curr Pediatr Res, 2012. 16(2): p. 83-94.
10. Lichtenstein, G.R., et al., ACG clinical guideline: management of Crohn's disease in adults. Official journal of the American College of Gastroenterology| ACG, 2018. 113(4): p. 481-517.
11. Ye, B.D., et al., Changes in the long-term prognosis of Crohn’s disease between 1986 and 2015: the population-based Songpa-Kangdong inflammatory bowel disease cohort study. Gut and Liver, 2022. 16(2): p. 216.
12. Rutgeerts, P., et al., Predictability of the postoperative course of Crohn's disease. Gastroenterology, 1990. 99(4): p. 956-963.
13. Gismera, C.S. and B.S. Aladrén, Inflammatory bowel diseases: a disease (s) of modern times? Is incidence still increasing? World Journal of Gastroenterology: WJG, 2008. 14(36): p. 5491.
14. Molodecky, N.A., et al., Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology, 2012. 142(1): p. 46-54. e42.
15. Langholz, E., P. Munkholm, M. Davidsen, and V. Binder, Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology, 1994. 107(1): p. 3-11.
16. Bouguen, G. and L. Peyrin-Biroulet, Surgery for adult Crohn's disease: what is the actual risk? Gut, 2011. 60(9): p. 1178-1181.
17. Molander, P., et al., Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD. Journal of Crohn's and Colitis, 2013. 7(9): p. 730-735.
18. Molander, P., et al., Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents. Inflammatory bowel diseases, 2012. 18(11): p. 2011-2017.
19. Nikolaus, S. and S. Schreiber, Diagnostics of inflammatory bowel disease. Gastroenterology, 2007. 133(5): p. 1670-1689.
20. Baars, J.E., et al., Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation. Inflammatory bowel diseases, 2012. 18(9): p. 1634-1640.
21. Rokkas, T., P. Portincasa, and I.E. Koutroubakis, Fecal calprotectin in assessing inflammatory bowel disease endoscopic activity: a diagnostic accuracy meta-analysis. Journal of Gastrointestinal and Liver Diseases, 2018. 27(3): p. 299-306.
22. Walsham, N.E. and R.A. Sherwood, Fecal calprotectin in inflammatory bowel disease. Clinical and experimental gastroenterology, 2016: p. 21-29.
23. Seo, J., et al., Fecal Calprotectin in Patients with Crohn’s Disease: A Study Based on the History of Bowel Resection and Location of Disease. Diagnostics, 2024. 14(8): p. 854.
24. Zittan, E., et al., Fecal calprotectin correlates with active colonic inflammatory bowel disease but not with small intestinal Crohn's disease activity. JGH Open, 2018. 2(5): p. 201-206.
25. Cremer, A., et al., Variability of faecal calprotectin in inflammatory bowel disease patients: an observational case-control study. Journal of Crohn's and Colitis, 2019. 13(11): p. 1372-1379.